Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

12
LULU Stock: Buy Lululemon and Its Track Record of Growth | InvestorPlace

3h investorplace
Lululemon Athelitca (NASDAQ:LULU) launched in 1998 and since then has pretty much stuck to its knitting — selling yoga clothes to women and girls.
LULU GPS NYTAB

8
Buy These 5 Low-Beta Stocks to Tackle Volatility Woes

4h zacks
Smart investors usually develop strategies after extensive research and avoid following the herd, which believes risky stocks can only generate lucrative returns.
LULU MED NAVG SAM

9
V.F. Corp (VFC) Stock Up on Q1 Earnings Beat & Raised View

5h zacks
V.F. Corporation (VFC - Free Report) beat earnings and revenue estimates in first-quarter fiscal 2019. Results gained from solid trends at its core brands (Vans and The North Face) and contributions from acquisitions. The company also witnessed strong growth at its international and direct-to-consumer businesses, as well as Active and Work segments. This marked the company’s fourth top- and bottom-line beat in the last five quarters.
UA UAA LULU GIII

12
How Luxury Brands Are Surviving the Millennial Revolution

2018-07-19 zacks
No matter what way you may want to look at Millennials, there is no denying that they are changing all industries and forcing companies to think about how to do business. This is especially true for luxury brands, as Millennials and Generation Z will represent more than 40% of the overall luxury goods market by 2025, according to a Deloitte industry report.
WFC WFCNP WFC.WS RL WFC.PRL WFC.PRJ ISRG WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN LULU WFC.PRY WFC.PRX WFC.PRW WFC.PRV

15
2 Athleisure Stocks That Are Primed for a Pairs Trade Strategy | InvestorPlace

2018-07-19 investorplace
Which athleisure stocks will tumble and which are poised to sprint higher? If investors are looking at Nike (NYSE:NKE) versus Lululemon (NASDAQ:LULU), maybe neither. But a combined wager on a runner-up and a name poised for another strong leg higher using an options-based pairs trade on NKE and LULU stock looks like a winning play.
NKE LULU

51
Don’t Rush to Pick Up L Brands as It Continues Its Downward Spiral

2018-07-18 investorplace
L Brands (NYSE:LB), which owns franchises like Victoria’s Secret, Bath & Body Works, and Pink, has been in a horrible downward spiral this year. The shares have plunged from $60 to $32.
AMZN NKE AEO LULU LB

8
A Beautiful Breakout Pattern Beckons in Lululemon Stock | InvestorPlace

2018-07-18 investorplace
Lululemon (NASDAQ:LULU) shares are beckoning to breakout traders. And with one of the best trends on the Street and momentum to boot, the invitations are very likely to be accepted. Today, we’ll chronicle the bullish pattern in LULU stock and build a trade idea to capitalize.
LULU NFLX

47
You Can't Go Wrong Buying Netflix On Dips - Cramer's Mad Money (7/17/18)

2018-07-18 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday, July 17.
GOOS WSM GILD NFLX ILMN W NDAQ VIRT CELG LULU URBN MCD BBBY

8
Snap-on (SNA) to Report Q2 Earnings: What's in the Cards?

2018-07-16 zacks
Snap-on Inc. (SNA - Free Report) is scheduled to report second-quarter 2018 results on Jul 19, before the opening bell. Notably, the company boasts an excellent surprise history, having surpassed earnings estimates for the last seven years. The Zacks Consensus Estimate for the second quarter is pegged at $2.95, which reflects an improvement of 13.5% year over year. However, the consensus mark moved south by a penny in the last 30 days.
NOC SNA KORS LULU

12
Can Whirlpool (WHR) Reverse Its Dismal Earnings Trend in Q2?

2018-07-16 zacks
Whirlpool Corp. (WHR - Free Report) is slated to release second-quarter 2018 results on Jul 23, after the closing bell. In the last reported quarter, the company reported a negative earnings surprise of 3.8%. Further, Whirlpool missed estimates in three of the last four quarters, with an average negative earnings surprise of 2.6%. Notably, the company has delivered negative earnings surprise in six of the last seven quarters.
WHR POOL GTT LULU

19
Zacks.com featured highlights include: Lululemon, Sirius XM, Nutrisystem and Illumina

2018-07-16 zacks
Chicago, IL – July 16, 2018 - Stocks in this week’s article Lululemon Athletica Inc. (LULU - Free Report) , Sirius XM Holdings Inc. (SIRI - Free Report) , Nutrisystem, Inc. (NTRI - Free Report) and Illumina, Inc. (ILMN - Free Report) .
RM NTRI AMC ETM.WI ILMN FITBI ETM SIRI MTCH ROSEU GTT LULU FITB PAA NMM ROSE

12
Will V.F. Corp's (VFC) Robust Earnings Trend Continue in Q1?

2018-07-13 zacks
V.F. Corporation (VFC - Free Report) is slated to release results for first-quarter fiscal 2019 on Jul 20, before the market opens. In the last reported quarter, this designer, manufacturer, and marketer of branded apparel and related products delivered a positive earnings surprise of 3.1%. This marked the company’s third top- and bottom-line beat in the last four quarters. The company recorded an average positive surprise of 3.
WFC WFCNP WFC.WS GES WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN LULU WFC.PRY WFC.PRX WFC.PRW WFC.PRV

8
4 Best Efficient Stocks to Add to Your Portfolio

2018-07-13 investorplace
Companies with favorable efficiency levels are likely to be on investors’ radar irrespective of market conditions. This is because a company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance.
SIRI NTRI LULU ILMN

8
4 Best Efficient Stocks to Add to Your Portfolio

2018-07-13 zacks
Companies with favorable efficiency levels are likely to be on investors’ radar irrespective of market conditions. This is because a company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance.
SIRI NTRI LULU ILMN

15
Canopy Buys Hiku In Push To Add Adult Brands

2018-07-13 seekingalpha
On Tuesday, after market close, Canopy (CGC) announced that it has agreed to acquire Hiku (OTCPK:DJACF) in an all-stock deal that values Hiku at $308 million on a fully diluted basis. Our initial thoughts are that Canopy paid a steep price for the assets that Hiku brings to the table. Most importantly, Canopy is paying hundreds of millions for an unproven concept that is likely to face intense competition after legalization.
LULU SBUX ATZAF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 550021109